HGEN News and Press, Humanigen Inc. From 03/10/21

Humanigen (HGEN) has obtained a term loan facility from Hercules Capital (HTGC) for up to $80M of secured debt financing.“The term loan facility provides working capital to support the production of lenzilumab, strengthens our balance sheet and increases our financial flexibility as we...

Company intends to use funds to support lenzilumab manufacturing and commercialization Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine s...

Lenzilumab™ clinical development program for COVID-19 advances from IND to completion of Phase 3 enrollment in fewer than 12 months Company completes two equity offerings in 2020, including uplisting to Nasdaq, to fund manufacturing scale-up and commercial preparation...

Anchiano Therapeutics (ANCN) +66%.Second Sight Medical Products (EYES) +38%.OpGen (OPGN) +29% after publication of final study results of Unyvero HPN Panel.Net Element (NETE) +19% on strategic partnership with Mullen technologies.Athene Holding Ltd. (ATH) +18%&#x...

Humanigen will release P3 clinical data for Lenzilumab in COVID-19 in late March. We believe that based on the pathophysiology, existing clinical data with GM-CSF blockage and the trial design, the study is more likely to be a success than not. In case of a positive trial readout,...

Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Co...

XTL Biopharmaceuticals (XTLB) +93%.Second Sight Medical Products, Inc. (EYES) +50%.Fulgent Genetics, Inc. (FLGT) +32% on Q4 results.CLPS Incorporation (CLPS) +29% on FQ2 results.Sify Technologies Limited (SIFY) +26% on report of Blackstone buying minority stake.Waitr Holdings (...

Humanigen (HGEN) earlier Tweeted that a trial for ACTIV-5 is not suspended after clinicaltrials.gov incorrectly listed the study as "suspended" on the order of IRB. The shares dropped 6.4% on the confusion.Humanigen said it confirmed that the trial is active and enrolling and has been as...

Humanigen (HGEN) announced that the company was awarded two patents by the United States Patent and Trademark Office (USPTO) covering its lead asset lenzilumab, a recombinant human GM-CSF antagonist.The patent win indicates the value of the company’s approach to neutralizing granulocyt...

First patent issued for the use of lenzilumab to reduce non-GM-CSF cytokines/chemokines that contribute to immunotherapy-related toxicity Second patent issued for the use of lenzilumab to improve the efficacy and durability of immunotherapy Humanigen, Inc. (Nasdaq: HGEN)...